ClinicalTrials.gg

Program

XTR004

A development code.

Its studies are mostly in Coronary Artery Disease, led by Sinotau Pharmaceutical Group.

Furthest: phase 3, since Jan 28, 20263 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinotau Pharmaceutical Group31 open or runningphase 3since Jan 28, 2026Dec 25, 2022Jun 2027phase 3 · NCT07439133

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 25, 2022First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT05885841 · 83 enrolled · China
  2. Sep 16, 2025Phase 2 study in Myocardial Perfusion ImagingNCT07187895 · 17 enrolled · China
  3. Jan 28, 2026Phase 3 study in Coronary Artery DiseasePhase 3 reachedNCT07439133 · 395 planned · China

Ahead

  1. Jun 2027Primary completion: phase 3 study in Coronary Artery DiseaseNCT07439133

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07439133Coronary Artery Disease · China3RecruitingJun 2027395
NCT07187895Myocardial Perfusion Imaging · China2TerminatedMar 5, 202517
NCT05885841Coronary Artery Disease · China2CompletedMay 9, 202383

How it is read

Names in the registry

  • “XTR004”, 3 entries

Codes read as this program: XTR004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.